However, considering that MDS and AML are among those HNs with less number of genes suffering de novo DNA methylation, we wonder whether part of the therapeutic effect of DNMT inhibitors is not due to demethylation of hypermethylated genes but rather a different mechanism, e.g. a cytotoxic effect. The gene discussed is DNMT1; the disease is acute myeloid leukemia.